Follicular Lymphoma
From the Journals
Anthracyclines, bendamustine are options for grade 3A follicular lymphoma
A CVP chemotherapy regimen performed poorly compared with anthracycline-based chemotherapy in advanced stage follicular lymphoma.
From the Journals
Daratumumab disappoints in non-Hodgkin lymphoma trial
The drug, used in multiple myeloma, was safe but ineffective in patients with non-Hodgkin lymphoma.
From the Journals
BCL expression intensity key in distinguishing FL lesions
BCL2 expression intensity is the “single most valuable clue” in differentiating primary cutaneous follicular center-cell lymphoma from secondary...
From the Journals
Study supports need for less toxic therapies in FL
The study examines causes of death for follicular lymphoma patients in the rituximab era.
New Therapies
Emerging biosimilars market presents opportunities and challenges
Conference Coverage
Phase 3 study confirms biosimilarity of PF-05280586 with rituximab
PF-05280586 showed biosimilarity to rituximab at up to 26 weeks in a randomized phase 3 study of treatment-naive patients with CD20-positive LTB-...
News
FDA approves biosimilar rituximab for NHL
The U.S.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
News
Biosimilar deemed equivalent to rituximab in FL
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL)....
News
Elderly NHL patients have higher NRM after HSCT
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of...